Soluble syndecans: biomarkers for diseases and therapeutic options

被引:68
作者
Bertrand, Jessica [1 ]
Bollmann, Miriam [1 ]
机构
[1] Otto von Guericke Univ, Dept Orthopaed Surg, Leipziger Str 44, D-39120 Magdeburg, Germany
关键词
FIBROBLAST-GROWTH-FACTOR; HEPARAN-SULFATE PROTEOGLYCANS; CELL-SURFACE PROTEOGLYCAN; ENDOTHELIAL GLYCOCALYX; SERUM-LEVELS; PROGNOSTIC-FACTOR; MULTIPLE-MYELOMA; FACTOR RECEPTOR; HEART-FAILURE; CIRCULATING SYNDECAN-1;
D O I
10.1111/bph.14397
中图分类号
R9 [药学];
学科分类号
100702 [药剂学];
摘要
Syndecans are important mediators of signalling by transmitting external stimuli into the cells. This role in signal transduction has been attributed mainly to the membrane-bound syndecans. In the last years, however, the soluble ectodomain of syndecans generated by shedding has come into the focus of research as this process has been show to modulate the syndecan-dependent signalling pathways, as well as other pathways. This review summarizes the current knowledge about the induction of syndecan shedding and the different pathways modulated by shed syndecan proteins. This review summarizes the known and putative sheddases for each syndecan and describes the exemplary conditions of sheddase activity for some syndecans. This review summarizes the proposed use of shed syndecans as biomarkers for various diseases, as the shedding process of syndecans depends crucially on tissue- and disease-specific activation of the sheddases. Furthermore, the potential use of soluble syndecans as a therapeutic option is discussed, on the basis of the current literature.
引用
收藏
页码:67 / 81
页数:15
相关论文
共 145 条
[1]
Syndecans - key regulators of cell signaling and biological functions [J].
Afratis, Nikolaos A. ;
Nikitovic, Dragana ;
Multhaupt, Hinke A. B. ;
Theocharis, Achilleas D. ;
Couchman, John R. ;
Karamanos, Nikos K. .
FEBS JOURNAL, 2017, 284 (01) :27-41
[2]
Albert Venencia, 2018, Med Sci (Basel), V6, DOI 10.3390/medsci6010005
[3]
THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: Catalytic receptors [J].
Alexander, Stephen P. H. ;
Fabbro, Doriano ;
Kelly, Eamonn ;
Marrion, Neil V. ;
Peters, John A. ;
Faccenda, Elena ;
Harding, Simon D. ;
Pawson, Adam J. ;
Sharman, Joanna L. ;
Southan, Christopher ;
Davies, Jamie A. .
BRITISH JOURNAL OF PHARMACOLOGY, 2017, 174 :S225-S271
[4]
Alexander SPH, 2017, BRIT J PHARMACOL, V174, pS272, DOI [10.1111/bph.13877, 10.1111/bph.13882]
[5]
[Anonymous], J THORAC CARDIOVASC
[6]
[Anonymous], PEDIAT INFECT DIS J
[7]
Pretreatment serum syndecan-1 levels and outcome in small cell lung cancer patients treated with platinum-based chemotherapy [J].
Anttonen, A ;
Leppä, S ;
Ruotsalainen, T ;
Alfthan, H ;
Mattson, K ;
Joensuu, H .
LUNG CANCER, 2003, 41 (02) :171-177
[8]
Aref Salah, 2003, Hematology, V8, P221, DOI 10.1080/1024533031000153630
[9]
Protein ectodomain shedding [J].
Arribas, J ;
Borroto, A .
CHEMICAL REVIEWS, 2002, 102 (12) :4627-4637
[10]
Matrix metalloproteinase-dependent shedding of syndecan-3, a transmembrane heparan sulfate proteoglycan, in Schwann cells [J].
Asundi, VK ;
Erdman, R ;
Stahl, RC ;
Carey, DJ .
JOURNAL OF NEUROSCIENCE RESEARCH, 2003, 73 (05) :593-602